Why the study?
Does pharmaceutical heart rate reduction improve prognosis in CVD-free patients for primary prevention?
Does pharmaceutical heart rate reduction improve prognosis in CVD-free patients for primary prevention?
While heart rate is an independent risk factor for cardiovascular disease, evidence for pharmaceutical heart rate reduction in primary prevention remains contradictory.
Should not yet change practice for primary prevention; leaves open efficacy of heart rate reduction in CVD-free patients.
Recently published studies have demonstrated a direct link between heart rate (HR) and prognosis across various populations and clinical groups, including elderly people, patients with arterial hypertension, myocardial infarction, and coronary artery stenting, overweight patients, or even young people with relatively low cardiovascular risk levels. HR is considered as an additional independent risk factor (RF) of cardiovascular disease (CVD). However, thus far, pharmaceutical HR reduction has been demonstrated to improve prognosis only in patients with coronary heart disease or chronic heart failure. The results in CVD-free patients have been contradictory. The review discusses the potential of different HR-reducing therapeutic regimens, as a part of primary CVD prevention.
No takes yet. Share an insight, caveat, or question.
Orlova et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: